| Literature DB >> 33671798 |
Anna Gromotowicz-Poplawska1, Piotr Szoka2, Agnieszka Zakrzeska3, Patrycjusz Kolodziejczyk4, Natalia Marcinczyk1, Janusz Szemraj5, Piotr Tutka4,6, Ewa Chabielska1.
Abstract
We investigated the role of aldosterone (ALDO) in the development of arterial thrombosis in streptozotocin-induced diabetic rats. To evaluate the effect of endogenous ALDO, the rats underwent adrenalectomy (ADX). ADX reduced the development of arterial thrombosis. A 1 h infusion of ALDO (30 μg/kg/h) enhanced thrombosis in adrenalectomized rats, while this effect was potentiated in diabetic rats. ALDO shortened bleeding time, increased plasma levels of tissue factor (TF) and plasminogen activator inhibitor, decreased plasma level of nitric oxide (NO) metabolites, and increased oxidative stress. Moreover, 2 h incubation of human umbilical vein endothelial cells (HUVECs) with ALDO (10-7 M) disrupted hemostatic balance in endothelial cells in normoglycemia (glucose 5.5 mM), and this effect was more pronounced in hyperglycemia (glucose 30 mM). We demonstrated that the acute ALDO infusion enhances arterial thrombosis in rats and hyperglycemia potentiates this prothrombotic effect. The mechanism of ALDO action was partially mediated by mineralocorticoid (MR) and glucocorticoid (GR) receptors and related to impact of the hormone on primary hemostasis, TF-dependent coagulation cascade, fibrinolysis, NO bioavailability, and oxidative stress balance. Our in vitro study confirmed that ALDO induces prothrombotic phenotype in the endothelium, particularly under hyperglycemic conditions.Entities:
Keywords: adrenalectomy; aldosterone; diabetes; glucocorticoid receptor; mineralocorticoid receptor; thrombosis
Year: 2021 PMID: 33671798 DOI: 10.3390/cells10020471
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600